NR 565 ADVANCED PHARMACOLOGY FINAL EXAM
REVIEW 2026/2027 | Chamberlain | Pass Guaranteed -
A+ Graded
SECTION 1: Pharmacokinetics & Pharmacodynamics (Q1-Q14)
Q1: Which pharmacokinetic parameter is defined as the ratio of the lethal dose for 50%
of the population to the effective dose for 50% of the population, and serves as a
measure of drug safety?
A. Therapeutic index [CORRECT]
B. Bioavailability
C. Volume of distribution
D. Clearance
Correct Answer: A
Rationale: The therapeutic index (TI = LD50/ED50 or TD50/ED50) quantifies the margin
of safety between a drug's therapeutic and toxic effects. A higher TI indicates a wider
safety margin. Bioavailability measures absorption extent, volume of distribution relates
drug concentration to total amount in body, and clearance measures elimination rate.
Q2: A 68-year-old patient taking simvastatin is prescribed clarithromycin for
community-acquired pneumonia. The nurse practitioner recognizes this combination
increases risk for myopathy because clarithromycin is a potent inhibitor of which
enzyme?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4 [CORRECT]
Correct Answer: D
Rationale: Clarithromycin is a potent CYP3A4 inhibitor that reduces simvastatin
metabolism, increasing statin plasma levels and myopathy/rhabdomyolysis risk.
Simvastatin is primarily metabolized by CYP3A4, not CYP1A2, CYP2C9, or CYP2D6. The
,combination requires either statin discontinuation or substitution with a non-CYP3A4
statin like pravastatin.
Q3: A patient taking warfarin begins fluconazole for esophageal candidiasis. Which type
of drug interaction occurs, and what is the expected effect on INR?
A. Pharmacodynamic interaction; decreased INR
B. Pharmacokinetic interaction; increased INR [CORRECT]
C. Pharmacokinetic interaction; decreased INR
D. Pharmacodynamic interaction; no change in INR
Correct Answer: B
Rationale: Fluconazole inhibits CYP2C9 and CYP3A4, reducing warfarin metabolism and
increasing plasma concentration (pharmacokinetic interaction). This elevates INR and
bleeding risk. Pharmacodynamic interactions involve additive or antagonistic effects at
receptor sites without altering drug concentrations.
Q4: A highly protein-bound drug (98% bound to albumin) is prescribed to a patient with
hypoalbuminemia. What is the primary clinical concern?
A. Decreased drug absorption
B. Increased free drug concentration and potential toxicity [CORRECT]
C. Increased drug half-life
D. Decreased volume of distribution
Correct Answer: B
Rationale: When albumin is low, less drug binds to protein, increasing the free (unbound)
fraction that is pharmacologically active. This increases the risk of toxicity even with
normal total drug levels. Absorption and half-life are not directly affected by protein
binding changes, and Vd typically increases with decreased protein binding.
Q5: A drug has a half-life of 6 hours. Approximately how long will it take to reach 94% of
steady-state concentration after initiating continuous infusion?
A. 12 hours
B. 18 hours
C. 24 hours [CORRECT]
D. 30 hours
Correct Answer: C
,Rationale: Steady state is reached after approximately 4 to 5 half-lives (93.75% at 4
half-lives, 96.875% at 5 half-lives). With a 6-hour half-life, 4 half-lives equal 24 hours,
achieving approximately 94% of steady state. Three half-lives (18 hours) achieves only
87.5%, while 5 half-lives (30 hours) exceeds 94%.
Q6: Which phase of drug metabolism primarily involves oxidation, reduction, and
hydrolysis reactions mediated by the cytochrome P450 enzyme system?
A. Phase I [CORRECT]
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: A
Rationale: Phase I reactions involve functionalization through oxidation, reduction, and
hydrolysis, primarily via CYP450 enzymes. Phase II reactions involve conjugation
(glucuronidation, sulfation, acetylation) to increase water solubility. Phase III refers to
transporter-mediated elimination, and Phase IV is not a standard pharmacokinetic
phase.
Q7: A patient on digoxin presents with nausea, vomiting, and yellow-tinted vision. Which
pharmacodynamic concept best explains why these symptoms occur with only a
modest increase in serum concentration?
A. High bioavailability
B. Narrow therapeutic index [CORRECT]
C. Low volume of distribution
D. High protein binding
Correct Answer: B
Rationale: Digoxin has a narrow therapeutic index, meaning the toxic dose is close to
the therapeutic dose, producing toxicity with small concentration increases. Nausea,
vomiting, and visual disturbances (yellow halos) are classic digoxin toxicity signs.
Bioavailability, Vd, and protein binding do not directly explain this sensitivity.
Q8: A patient prescribed codeine for postoperative pain reports no analgesic effect.
Genetic testing reveals the patient is a CYP2D6 poor metabolizer. What is the clinical
significance?
, A. Codeine is metabolized to an inactive metabolite
B. Codeine cannot be converted to morphine, resulting in inadequate analgesia
[CORRECT]
C. The patient will experience excessive sedation
D. Codeine clearance is increased
Correct Answer: B
Rationale: Codeine is a prodrug requiring CYP2D6-mediated conversion to morphine for
analgesic effect. Poor metabolizers cannot efficiently perform this conversion, resulting
in subtherapeutic morphine levels and inadequate pain relief. Ultra-rapid metabolizers
would produce excessive morphine and sedation.
Q9: A drug that produces 50% of the maximum possible response at a lower dose than
its comparator is best described as having greater:
A. Efficacy
B. Potency [CORRECT]
C. Therapeutic index
D. Intrinsic activity
Correct Answer: B
Rationale: Potency refers to the dose required to produce a given effect; a lower EC50
indicates higher potency. Efficacy refers to the maximum effect achievable regardless
of dose. Therapeutic index relates safety, and intrinsic activity describes receptor
activation capability, not dose sensitivity.
Q10: A patient taking dabigatran is started on dronedarone for atrial fibrillation. The
nurse practitioner recognizes this combination increases bleeding risk because
dronedarone inhibits which transporter that affects dabigatran elimination?
A. OATP1B1
B. P-glycoprotein [CORRECT]
C. BCRP
D. MRP2
Correct Answer: B
Rationale: Dabigatran is a P-glycoprotein (P-gp) substrate, and dronedarone is a P-gp
inhibitor. Inhibiting P-gp reduces dabigatran renal elimination, increasing plasma
concentration and bleeding risk. OATP1B1 transports statins, while BCRP and MRP2 are
less relevant to this specific interaction.
REVIEW 2026/2027 | Chamberlain | Pass Guaranteed -
A+ Graded
SECTION 1: Pharmacokinetics & Pharmacodynamics (Q1-Q14)
Q1: Which pharmacokinetic parameter is defined as the ratio of the lethal dose for 50%
of the population to the effective dose for 50% of the population, and serves as a
measure of drug safety?
A. Therapeutic index [CORRECT]
B. Bioavailability
C. Volume of distribution
D. Clearance
Correct Answer: A
Rationale: The therapeutic index (TI = LD50/ED50 or TD50/ED50) quantifies the margin
of safety between a drug's therapeutic and toxic effects. A higher TI indicates a wider
safety margin. Bioavailability measures absorption extent, volume of distribution relates
drug concentration to total amount in body, and clearance measures elimination rate.
Q2: A 68-year-old patient taking simvastatin is prescribed clarithromycin for
community-acquired pneumonia. The nurse practitioner recognizes this combination
increases risk for myopathy because clarithromycin is a potent inhibitor of which
enzyme?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4 [CORRECT]
Correct Answer: D
Rationale: Clarithromycin is a potent CYP3A4 inhibitor that reduces simvastatin
metabolism, increasing statin plasma levels and myopathy/rhabdomyolysis risk.
Simvastatin is primarily metabolized by CYP3A4, not CYP1A2, CYP2C9, or CYP2D6. The
,combination requires either statin discontinuation or substitution with a non-CYP3A4
statin like pravastatin.
Q3: A patient taking warfarin begins fluconazole for esophageal candidiasis. Which type
of drug interaction occurs, and what is the expected effect on INR?
A. Pharmacodynamic interaction; decreased INR
B. Pharmacokinetic interaction; increased INR [CORRECT]
C. Pharmacokinetic interaction; decreased INR
D. Pharmacodynamic interaction; no change in INR
Correct Answer: B
Rationale: Fluconazole inhibits CYP2C9 and CYP3A4, reducing warfarin metabolism and
increasing plasma concentration (pharmacokinetic interaction). This elevates INR and
bleeding risk. Pharmacodynamic interactions involve additive or antagonistic effects at
receptor sites without altering drug concentrations.
Q4: A highly protein-bound drug (98% bound to albumin) is prescribed to a patient with
hypoalbuminemia. What is the primary clinical concern?
A. Decreased drug absorption
B. Increased free drug concentration and potential toxicity [CORRECT]
C. Increased drug half-life
D. Decreased volume of distribution
Correct Answer: B
Rationale: When albumin is low, less drug binds to protein, increasing the free (unbound)
fraction that is pharmacologically active. This increases the risk of toxicity even with
normal total drug levels. Absorption and half-life are not directly affected by protein
binding changes, and Vd typically increases with decreased protein binding.
Q5: A drug has a half-life of 6 hours. Approximately how long will it take to reach 94% of
steady-state concentration after initiating continuous infusion?
A. 12 hours
B. 18 hours
C. 24 hours [CORRECT]
D. 30 hours
Correct Answer: C
,Rationale: Steady state is reached after approximately 4 to 5 half-lives (93.75% at 4
half-lives, 96.875% at 5 half-lives). With a 6-hour half-life, 4 half-lives equal 24 hours,
achieving approximately 94% of steady state. Three half-lives (18 hours) achieves only
87.5%, while 5 half-lives (30 hours) exceeds 94%.
Q6: Which phase of drug metabolism primarily involves oxidation, reduction, and
hydrolysis reactions mediated by the cytochrome P450 enzyme system?
A. Phase I [CORRECT]
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: A
Rationale: Phase I reactions involve functionalization through oxidation, reduction, and
hydrolysis, primarily via CYP450 enzymes. Phase II reactions involve conjugation
(glucuronidation, sulfation, acetylation) to increase water solubility. Phase III refers to
transporter-mediated elimination, and Phase IV is not a standard pharmacokinetic
phase.
Q7: A patient on digoxin presents with nausea, vomiting, and yellow-tinted vision. Which
pharmacodynamic concept best explains why these symptoms occur with only a
modest increase in serum concentration?
A. High bioavailability
B. Narrow therapeutic index [CORRECT]
C. Low volume of distribution
D. High protein binding
Correct Answer: B
Rationale: Digoxin has a narrow therapeutic index, meaning the toxic dose is close to
the therapeutic dose, producing toxicity with small concentration increases. Nausea,
vomiting, and visual disturbances (yellow halos) are classic digoxin toxicity signs.
Bioavailability, Vd, and protein binding do not directly explain this sensitivity.
Q8: A patient prescribed codeine for postoperative pain reports no analgesic effect.
Genetic testing reveals the patient is a CYP2D6 poor metabolizer. What is the clinical
significance?
, A. Codeine is metabolized to an inactive metabolite
B. Codeine cannot be converted to morphine, resulting in inadequate analgesia
[CORRECT]
C. The patient will experience excessive sedation
D. Codeine clearance is increased
Correct Answer: B
Rationale: Codeine is a prodrug requiring CYP2D6-mediated conversion to morphine for
analgesic effect. Poor metabolizers cannot efficiently perform this conversion, resulting
in subtherapeutic morphine levels and inadequate pain relief. Ultra-rapid metabolizers
would produce excessive morphine and sedation.
Q9: A drug that produces 50% of the maximum possible response at a lower dose than
its comparator is best described as having greater:
A. Efficacy
B. Potency [CORRECT]
C. Therapeutic index
D. Intrinsic activity
Correct Answer: B
Rationale: Potency refers to the dose required to produce a given effect; a lower EC50
indicates higher potency. Efficacy refers to the maximum effect achievable regardless
of dose. Therapeutic index relates safety, and intrinsic activity describes receptor
activation capability, not dose sensitivity.
Q10: A patient taking dabigatran is started on dronedarone for atrial fibrillation. The
nurse practitioner recognizes this combination increases bleeding risk because
dronedarone inhibits which transporter that affects dabigatran elimination?
A. OATP1B1
B. P-glycoprotein [CORRECT]
C. BCRP
D. MRP2
Correct Answer: B
Rationale: Dabigatran is a P-glycoprotein (P-gp) substrate, and dronedarone is a P-gp
inhibitor. Inhibiting P-gp reduces dabigatran renal elimination, increasing plasma
concentration and bleeding risk. OATP1B1 transports statins, while BCRP and MRP2 are
less relevant to this specific interaction.
